A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
复制标题
血浆交换的随机对照临床试验，用白蛋白替代阿尔茨海默氏病：Ambar研究的主要结果。
DOI：
10.1002/alz.12137
复制
发表时间：
2020-10
期刊：
影响因子：
--
通讯作者：
Páez A
中科院分区：
文献类型：
--
作者：
Boada M;López OL;Olazarán J;Núñez L;Pfeffer M;Paricio M;Lorites J;Piñol-Ripoll G;Gámez JE;Anaya F;Kiprov D;Lima J;Grifols C;Torres M;Costa M;Bozzo J;Szczepiorkowski ZM;Hendrix S;Páez A
这项2b/3期试验检查了血浆置换（PE）对轻度至中度阿尔茨海默病（AD）患者的影响。将347例患者（496例筛选患者）随机（1：1：1：1）分配至3个PE治疗组，分别接受不同剂量的白蛋白和静脉注射免疫球蛋白替代治疗（6周每周常规PE治疗，随后12个月每月低容量PE治疗）和安慰剂（假手术）。PE治疗患者在协同主要终点方面的表现显著优于安慰剂：第14个月时阿尔茨海默病合作研究-日常生活活动（ADCS‐ADL; P = 0.03;下降幅度减少52%）较基线的变化以及阿尔茨海默病评估量表-认知子量表（ADAS‐Cog; P = 0.06;下降幅度减少66%）评分的趋势。中度AD患者（基线简易精神状态检查[MMSE] 18 - 21）在ADCS-ADL（P = .002）和ADAS-Cog（P = .05）方面得分更高，下降幅度均减少61%。轻度AD患者（MMSE 22 - 26）无变化。PE治疗的患者在临床痴呆评分总和（CDR-sb）（P = .002;下降减少71%）和阿尔茨海默病合作研究-临床总体印象变化（ADCS-CGIC）（P < .0001;下降减少100%）量表上得分更高。这项试验表明，PE与白蛋白替代可以减缓AD的认知和功能下降，但需要进一步的研究。
This phase 2b/3 trial examined the effects of plasma exchange (PE) in patients with mild‐to‐moderate Alzheimer's disease (AD). Three hundred forty‐seven patients (496 screened) were randomized (1:1:1:1) into three PE treatment arms with different doses of albumin and intravenous immunoglobulin replacement (6‐week period of weekly conventional PE followed by a 12‐month period of monthly low‐volume PE), and placebo (sham). PE‐treated patients performed significantly better than placebo for the co‐primary endpoints: change from baseline of Alzheimer's Disease Cooperative Study–Activities of Daily Living (ADCS‐ADL; P = .03; 52% less decline) with a trend for Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog; P = .06; 66% less decline) scores at month 14. Moderate‐AD patients (baseline Mini‐Mental State Examination [MMSE] 18‐21) scored better on ADCS‐ADL (P = .002) and ADAS‐Cog (P = .05), 61% less decline both. There were no changes in mild‐AD patients (MMSE 22‐26). PE‐treated patients scored better on the Clinical Dementia Rating Sum of Boxes (CDR‐sb) (P = .002; 71% less decline) and Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change (ADCS‐CGIC) (P < .0001; 100% less decline) scales. This trial suggests that PE with albumin replacement could slow cognitive and functional decline in AD, although further studies are warranted.
登录
查看更多内容
影响因子：
2.6
作者：
Alsina, Laia;Mohr, Andreas;Gompels, Mark
通讯作者：
Gompels, Mark
人血浆中的β-淀粉样动力学。
影响因子：
--
作者：
Huang Y;Potter R;Sigurdson W;Kasten T;Connors R;Morris JC;Benzinger T;Mintun M;Ashwood T;Ferm M;Budd SL;Bateman RJ
通讯作者：
Bateman RJ
DOI：
10.3233/jad-170693
发表时间：
2018
期刊：
Journal of Alzheimer's disease : JAD
影响因子：
--
作者：
Cuberas-Borrós G;Roca I;Boada M;Tárraga L;Hernández I;Buendia M;Rubio L;Torres G;Bittini Á;Guzmán-de-Villoria JA;Pujadas F;Torres M;Núñez L;Castell J;Páez A
通讯作者：
Páez A
影响因子：
--
作者：
Boada, Merce;Ortiz, Pilar;Paez, Antonio
通讯作者：
Paez, Antonio
DOI：
10.1016/j.trci.2019.01.001
发表时间：
2019-01-01
影响因子：
4.8
作者：
Boada, Merce;Lopez, Oscar;Paez, Antonio
通讯作者：
Paez, Antonio